A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions
Condition(s):Nausea; VomitingLast Updated:January 23, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Nausea; VomitingLast Updated:January 23, 2018Completed
Condition(s):Postoperative Nausea and VomitingLast Updated:December 18, 2019Completed
Condition(s):GastroparesisLast Updated:February 14, 2022Withdrawn
Condition(s):Chemotherapy-induced Nausea and Vomiting (CINV)Last Updated:June 3, 2021Unknown status
Condition(s):Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell TumorLast Updated:March 15, 2016Completed
Condition(s):Antiggaging Effect; Antiemetic; Granisetron; Gag Reflex; Dental SituationsLast Updated:November 30, 2010Unknown status
Condition(s):Chemotherapy-induced Nausea and VomitingLast Updated:April 12, 2023Completed
Condition(s):Chemotherapy-induced Nausea and VomitingLast Updated:April 13, 2022Unknown status
Condition(s):Nausea; Vomiting; CancerLast Updated:January 11, 2017Unknown status
Condition(s):Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:January 6, 2014Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.